InMode Ltd (NASDAQ:INMD) reported Q2 sales of $136.1 million, an increase of 20% Y/Y, beating the consensus of $132 million and slightly above the preliminary numbers.
Adjusted EPS reached $0.72, compared to $0.59 a year ago, beating the consensus of $0.64.
InMode’s surgical technology platforms engaged in minimally invasive & subdermal ablative treatments represented 81% of quarterly revenues, while 9% came from InMode’s hands-free platforms and 10% from traditional laser & non-invasive RF platforms.
Adjusted gross margin remains unchanged at 54%.
“We are pleased to report a record quarter with revenue of $136.1 million, as sales from our platforms and disposables were the strongest they’ve ever been,” said Moshe Mizrahy, Chairman & CEO.
Shakil Lakhani, President of InMode North America, commented, “Once again, we saw an increase in consumable and platform sales in the second quarter. Revenue from consumables and service for the second quarter grew nearly 44% year-over-year and reached a record level.”
Guidance: InMode expects FY23 sales of $530 million-$540 million compared to the consensus of $533.1 million.
The company forecasts adjusted EPS of $2.62-$2.66 compared to the Wall Street estimate of $2.63.
Price Action: INMD shares are up 6.04% at $47.82 on the last check Thursday.
